Logo image of COCH

ENVOY MEDICAL INC (COCH) Stock Fundamental Analysis

USA - NASDAQ:COCH - US29415V1098 - Common Stock

0.7294 USD
+0.03 (+3.93%)
Last: 11/12/2025, 8:08:32 PM
0.7308 USD
+0 (+0.19%)
After Hours: 11/12/2025, 8:08:32 PM
Fundamental Rating

0

Overall COCH gets a fundamental rating of 0 out of 10. We evaluated COCH against 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of COCH have multiple concerns. COCH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

COCH had negative earnings in the past year.
COCH had a negative operating cash flow in the past year.
In the past 5 years COCH reported 4 times negative net income.
COCH had a negative operating cash flow in each of the past 5 years.
COCH Yearly Net Income VS EBIT VS OCF VS FCFCOCH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

COCH's Return On Assets of -284.89% is on the low side compared to the rest of the industry. COCH is outperformed by 96.30% of its industry peers.
Industry RankSector Rank
ROA -284.89%
ROE N/A
ROIC N/A
ROA(3y)-205.35%
ROA(5y)-123.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COCH Yearly ROA, ROE, ROICCOCH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for COCH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COCH Yearly Profit, Operating, Gross MarginsCOCH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

0

2. Health

2.1 Basic Checks

COCH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for COCH has been increased compared to 1 year ago.
The debt/assets ratio for COCH is higher compared to a year ago.
COCH Yearly Shares OutstandingCOCH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
COCH Yearly Total Debt VS Total AssetsCOCH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -48.42, we must say that COCH is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of COCH (-48.42) is worse than 92.06% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -48.42
ROIC/WACCN/A
WACC6.17%
COCH Yearly LT Debt VS Equity VS FCFCOCH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 0.94 indicates that COCH may have some problems paying its short term obligations.
COCH's Current ratio of 0.94 is on the low side compared to the rest of the industry. COCH is outperformed by 89.42% of its industry peers.
COCH has a Quick Ratio of 0.94. This is a bad value and indicates that COCH is not financially healthy enough and could expect problems in meeting its short term obligations.
COCH has a Quick ratio of 0.74. This is amonst the worse of the industry: COCH underperforms 86.24% of its industry peers.
Industry RankSector Rank
Current Ratio 0.94
Quick Ratio 0.74
COCH Yearly Current Assets VS Current LiabilitesCOCH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M

1

3. Growth

3.1 Past

COCH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -90.24%.
COCH shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -26.49%.
EPS 1Y (TTM)-90.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.52%
Revenue 1Y (TTM)-26.49%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.71%

3.2 Future

The Earnings Per Share is expected to grow by 4.64% on average over the next years.
The Revenue is expected to grow by 3.82% on average over the next years.
EPS Next Y13.56%
EPS Next 2Y4.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-17.84%
Revenue Next 2Y3.82%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

COCH Yearly Revenue VS EstimatesCOCH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 100K 200K 300K
COCH Yearly EPS VS EstimatesCOCH Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -0.5 -1 -1.5

0

4. Valuation

4.1 Price/Earnings Ratio

COCH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for COCH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COCH Price Earnings VS Forward Price EarningsCOCH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COCH Per share dataCOCH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.64%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

COCH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ENVOY MEDICAL INC

NASDAQ:COCH (11/12/2025, 8:08:32 PM)

After market: 0.7308 +0 (+0.19%)

0.7294

+0.03 (+3.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)11-24 2025-11-24/amc
Inst Owners56.67%
Inst Owner Change-0.61%
Ins Owners49.46%
Ins Owner Change1.84%
Market Cap20.92M
Revenue(TTM)222.00K
Net Income(TTM)-28.20M
Analysts82.22
Price Target7.99 (995.42%)
Short Float %5.24%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.12
Dividend Growth(5Y)N/A
DP-15.13%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.59%
Min EPS beat(2)-1.2%
Max EPS beat(2)16.38%
EPS beat(4)1
Avg EPS beat(4)-14.25%
Min EPS beat(4)-39.48%
Max EPS beat(4)16.38%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-7.35%
Min Revenue beat(2)-32.36%
Max Revenue beat(2)17.65%
Revenue beat(4)1
Avg Revenue beat(4)-24.85%
Min Revenue beat(4)-50.59%
Max Revenue beat(4)17.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.44%
PT rev (3m)9.94%
EPS NQ rev (1m)-1.09%
EPS NQ rev (3m)2.11%
EPS NY rev (1m)4.31%
EPS NY rev (3m)5.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 94.23
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0.01
BVpS-1.04
TBVpS-1.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -284.89%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-205.35%
ROA(5y)-123.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 259.26%
Cap/Sales 283.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.94
Quick Ratio 0.74
Altman-Z -48.42
F-Score2
WACC6.17%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.52%
EPS Next Y13.56%
EPS Next 2Y4.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.49%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.71%
Revenue Next Year-17.84%
Revenue Next 2Y3.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-268.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-253.54%
OCF growth 3YN/A
OCF growth 5YN/A

ENVOY MEDICAL INC / COCH FAQ

What is the fundamental rating for COCH stock?

ChartMill assigns a fundamental rating of 0 / 10 to COCH.


Can you provide the valuation status for ENVOY MEDICAL INC?

ChartMill assigns a valuation rating of 0 / 10 to ENVOY MEDICAL INC (COCH). This can be considered as Overvalued.


How profitable is ENVOY MEDICAL INC (COCH) stock?

ENVOY MEDICAL INC (COCH) has a profitability rating of 0 / 10.


Is the dividend of ENVOY MEDICAL INC sustainable?

The dividend rating of ENVOY MEDICAL INC (COCH) is 0 / 10 and the dividend payout ratio is -15.13%.